Table 2.
Summary of patient characteristics
| Characteristics | Responders (n = 12) | Non-responders (n = 12) | P value |
|---|---|---|---|
| Age – no. (%) | |||
| > 65 | 6 (50%) | 2 (17%) | 0.083 |
| ≤ 65 | 6 (50%) | 10 (83%) | |
| Sex – no. (%) | |||
| Male | 9 (75%) | 9 (75%) | >0.999 |
| Female | 3 (25%) | 3 (25%) | |
| LDH – no. (%) | |||
| > 1× ULN | 1 (8%) | 8 (67%) | 0.0032 |
| ≤ 1× ULN | 11 (92%) | 4 (33%) | |
| Disease volume – no. (%) | |||
| SPOD > 1000 mm2 | 7 (58%) | 10 (83%) | 0.178 |
| SPOD ≤ 1000 mm2 | 5 (42%) | 2 (17%) | |
| AJCC tumor stage – no. (%) | |||
| M1a or M1b | 6 (50%) | 1 (8%) | 0.025 |
| M1c | 6 (50%) | 11 (92%) | |
| Mutation – no. (%) | |||
| BRAFV600E/K | 3 (25%) | 5 (42%) | 0.3865 |
| Non-BRAFV600E/K | 9 (75%) | 7 (58%) | |
Abbreviations: LDH lactate dehydrogenase, SPOD sum of product of diameters, AJCC American Joint Committee on Cancer, ULN upper limit of normal. The p value was calculated using the Chi square test for a two by two contingency table